Capricor Therapeutics (NASDAQ:CAPR) and Parent Project Muscular
Dystrophy (PPMD) will host a webinar at 1 p.m. ET on July 18 to
provide information about the HOPE-2 clinical trial, which is
evaluating the safety and efficacy of repeat doses of CAP-1002 in
boys and young men with Duchenne muscular dystrophy and reduced
upper limb function.
HOPE-2 is a Phase II, randomized, double-blind,
placebo-controlled clinical trial that will randomize up to 84
participants at approximately 10-15 medical centers in the United
States.
An earlier clinical trial, HOPE-Duchenne, found a single
intracoronary dose of CAP-1002 in participants in advanced stages
of Duchenne muscular dystrophy was generally safe and well
tolerated. The trial also found significant and sustained
improvement in cardiac and skeletal muscle function among those
receiving CAP-1002 when compared to participants who received usual
care only.
“Please join PPMD and Capricor as we host this webinar to
provide a brief background of CAP-1002 and its clinical development
leading up to this exciting clinical trial,” said Linda Marbán,
Ph.D., Capricor chief executive officer. “We will review the design
of the HOPE-2 trial, eligibility criteria and assessments that
participants will need to complete to participate in the
trial.”
Capricor and PPMD Webinar
Date: Wednesday, July 18, 2018Time: 1-2 p.m. ET Connect via the
web: www.readytalk.com, access code: 9449985Connect via phone:
866.740.1260, access code: 9449985
Speakers
- Linda Marban, Ph.D., Capricor chief executive officer
- Pat Furlong, PPMD president
- Craig M. McDonald, M.D., HOPE-2 principal investigator and
professor of pediatrics at the University of California, Davis
- Deborah Ascheim, M.D., Capricor chief medical officer
For more information on HOPE-2, please visit
www.HOPE2Trial.com.
About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is a devastating genetic disorder
that causes muscle degeneration and leads to death, generally
before the age of 30, most commonly from heart failure. It occurs
in one in every 3,600 live male births across all races, cultures
and countries. Duchenne muscular dystrophy afflicts approximately
200,000 boys and young men around the world. Treatment options are
limited, and there is no cure.
About CAP-1002
CAP-1002 consists of allogeneic cardiosphere-derived cells, or
CDCs, a unique population of cells that contains cardiac progenitor
cells. CAP-1002 has been shown to exert potent immunomodulatory
activity and stimulate cellular regeneration. CDCs have been the
subject of over 100 peer-reviewed scientific publications and have
been administered to approximately 140 human subjects across
several clinical trials.
About Capricor Therapeutics Capricor
Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of first-in-class biological therapeutics for the treatment of rare
disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic
cell therapy that is currently in clinical development for the
treatment of Duchenne muscular dystrophy. Capricor has also
established itself as one of the leading companies investigating
the field of extracellular vesicles and is exploring the potential
of CAP-2003, a cell-free, exosome-based candidate, to treat a
variety of disorders. For more information, please visit
www.capricor.com.
Keep up with Capricor on social media:
www.facebook.com/capricortherapeutics,
www.instagram.com/capricortherapeutics/ and
https://twitter.com/capricor.
About Parent Project Muscular Dystrophy
Parent Project Muscular Dystrophy (PPMD) is the largest most
comprehensive nonprofit organization in the United States focused
on finding a cure for Duchenne muscular dystrophy—its mission is to
end Duchenne.
PPMD invests deeply in treatments for this generation of people
affected by Duchenne and in research that will benefit future
generations. It advocates in Washington, D.C., and has secured
hundreds of millions of dollars in funding. PPMD demands optimal
care, and it strengthens, unites and educates the global Duchenne
community.
Everything PPMD does—and everything it has done since its
founding in 1994—helps people with Duchenne live longer, stronger
lives. PPMD will not rest until every person has a treatment to end
Duchenne. Go to www.ParentProjectMD.org for more information or to
learn how to support its efforts and help families affected by
Duchenne. Follow PPMD on Facebook, Twitter and YouTube.
Cautionary Note Regarding Forward-Looking
Statements
Statements in this press release regarding the efficacy, safety,
and intended utilization of Capricor's product candidates; the
initiation, conduct, size, timing and results of discovery efforts
and clinical trials; the pace of enrollment of clinical trials;
plans regarding regulatory filings, future research and clinical
trials; regulatory developments involving products, including the
ability to obtain regulatory approvals or otherwise bring products
to market; plans regarding current and future collaborative
activities and the ownership of commercial rights; scope, duration,
validity and enforceability of intellectual property rights; future
royalty streams, expectations with respect to the expected use of
proceeds from the recently completed offerings and the anticipated
effects of the offerings, and any other statements about Capricor's
management team's future expectations, beliefs, goals, plans or
prospects constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including
statements containing the words "believes," "plans," "could,"
"anticipates," "expects," "estimates," "should," "target," "will,"
"would" and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors
that could cause actual results or events to differ materially from
those indicated by such forward-looking statements. More
information about these and other risks that may impact Capricor's
business is set forth in Capricor's Annual Report on Form 10-K for
the year ended December 31, 2017 as filed with the Securities and
Exchange Commission on March 22, 2018, in its Registration
Statement on Form S-3, as filed with the Securities and Exchange
Commission on September 28, 2015, together with the prospectus
included therein and prospectus supplements thereto and in its
Quarterly Report on Form 10-Q for the quarter ended March 31, 2018,
as filed with the Securities and Exchange Commission on May 14,
2018. All forward-looking statements in this press release are
based on information available to Capricor as of the date hereof,
and Capricor assumes no obligation to update these forward-looking
statements.
CAP-1002 is an Investigational New Drug and is
not approved for any indications. CAP-2003 has not yet been
approved for clinical investigation.
For more information, please contact:
AJ Bergmann, Chief Financial Officer
+1-310-358-3200
abergmann@capricor.com
Capricor Therapeutics (NASDAQ:CAPR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Capricor Therapeutics (NASDAQ:CAPR)
Historical Stock Chart
From Apr 2023 to Apr 2024